Aldosterone antagonists and renal denervation: Friends or foes?

Hypertension

Volumn 65, Issue 2, 2015, Pages 280-282

  Mahfoud, Felix ^a   Ruilope, Luis M ^b   Böhm, Michael ^a   Schmieder, Roland E ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CREATININE; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; KIDNEY FUNCTION; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRESSORECEPTOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SIDE EFFECT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; CATHETER ABLATION; FEMALE; HYPERTENSION; INNERVATION; KIDNEY; MALE; SYMPATHECTOMY;

ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SPIRONOLACTONE; SYMPATHECTOMY;

EID: 84921605197     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04119     Document Type: Editorial

References (18)

1. Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. Hypertension. 2014;63:e25-e32.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
3. Mahfoud F, Lüscher TF, Andersson B, et al; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-2157.
4. Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8:593-598.
5. Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six month results from the Prague-15 study. Hypertension. 2015;65:407-413.
6. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3-15.
7. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.
8. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094-2102.
9. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820-828.
10. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629.
11. Schmieder RE, Schmidt ST, Riemer T, Dechend R, Hagedorn I, Senges J, Messerli FH, Zeymer U. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension. 2014;64:1067-1072.
12. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880-1886.
13. Mahfoud F, Edelman ER, Böhm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64:644-646.
14. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
15. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial [published online ahead of print November 16, 2014]. Eur Heart J. doi: 10. 1093/eurheartj/ehu441. http://eurheartj. oxfordjournals. org/content/early/2014/11/13/eurheartj. ehu441. Accessed November 17, 2014.
16. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
17. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C; European Society of Hypertension. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013;9(suppl R):R58-R66.
18. Fontenla A, García-Donaire JA, Hernández F, Segura J, Salgado R, Cerezo C, Ruilope LM, Arribas F. Management of resistant hypertension in a multidisciplinary unit of renal denervation: protocol and results. Rev Esp Cardiol (Engl Ed). 2013;66:364-370.